quarter market
look great thesi unchang
overal result good nice stock run
earn though sinc end august vs think
market look great headlin result strong
revenu beat forecast adj ep beat
forecast said upsid driven contribut
ivd licens arrang notabl strip benefit
underli revenu modestli better expect consum
grew y/i also forecast encourag
commentari novaseq consum approach quarter
pull-through per instrument continu push higher estim
off-set partial lower-throughput custom transit
sequenc onto higher-throughput platform weigh mid-to-low
throughput pull-through quarter instrument grew y/i
forecast compani state novaseq shipment
second highest record nextseq adopt remain strong notabl clinic
custom shipment low-throughput shipment also increas sequenti
expect array revenu weak y/i impact pressur dtc
test discuss earlier year
turn maintain revenu outlook
assum conservat around forecast consum
array consum compani expect acceler
high-teen due partial easier comp lower origin
expect think runway remain strong back
contribut clinic popseq check continu suggest
strong demand adj ep move higher rang
previous primarili due margin pull-through
ivd collabor forecast move higher maintain
adj ep outlook remain confid overal sequenc
outlook reiter ow rate pt
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
overweight leader next
gener sequenc project
signific growth driven larg research studi
nascent opportun clinic diagnost
signific competit moat rel
competit given brand scale
growth forseeabl futur
compani instal base grow higher
consum revenu contribut margin
leverag estim upsid case
reflect upsid ep
growth ultim depend
custom fund includ govern grant
nih well clinic reimburs lower
downsid case reflect downsid
ep
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overal result good nice stock run earn
though sinc end august vs think market
look great headlin result strong revenu
beat forecast adj ep beat forecast said
upsid driven contribut ivd licens arrang
notabl strip benefit underli revenu modestli
better expect consum grew y/i also
forecast encourag commentari novaseq consum
approach quarter pull-through per instrument continu push
higher estim off-set partial lower-throughput custom
transit sequenc onto higher-throughput platform weigh
mid-to-low throughput pull-through quarter grew
y/i forecast compani state novaseq shipment
second highest record nextseq adopt remain strong notabl clinic
custom shipment low-throughput shipment also increas sequenti
expect array revenu weak y/i impact pressur dtc test
discuss earlier year
turn maintain revenu outlook
assum conservat around forecast consum
array consum compani expect acceler high-
teen due partial easier comp lower origin
expect think runway remain strong back
contribut clinic popseq check continu suggest strong
demand adj ep move higher rang
previous primarili due margin pull-through ivd
collabor forecast move higher maintain adj
ep outlook remain confid overal sequenc outlook
reiter ow rate pt
quarterli result reiter revenu guidanc rais ep
guidanc continu project revenu growth approxim
embed guidanc growth sequenc revenu novaseq shipment
continu expect flat slightli y/i given dtc test weak array
revenu anticip declin y/i vs previous ep
expect rang previous
repres growth gross margin expect slightli
y/i opex percentag revenu forecast improv y/i
guidanc also assum flat tax rate y/i flat share count y/i
revenu forecast grow y/i gross margin expect
sequenti basi due ivd contribut oper expens
expect similarli increas percentag revenu sequenti basi
incom expect sequenti tax rate anticip roughli
revenu grew y/i million million expect
revenu upsid came compani ivd collabor notabl
contribut revenu quarter geograph
perspect growth mostli solid quarter growth america
growth emea growth asia-pacif region revenu declin china
exclud stock order china revenu would declin y/i
result china benefit reproduct health oncolog test consum
off-set lower revenu research
revenu y/i growth
revenu increas y/i million total revenu
consum grew quarter sequenc consum grew platform
exclud hiseq novaseq consum almost quarter
believ impli pull-through roughli per instrument hiseq consum
around given total high-throughput consum around
quarter nextseq util low end guid rang
guidanc growth gross op base per sharenon-gaap interest extinguish debtleg contingenciescost-method investmentsconting compensationheadquart y/i slightli slightli growthrev mm revenu y/i growth barclay illumina inc
miseq util miss guidanc rang quarter manag
attribut weaker mid-to-low throughput trend custom transit workflow
onto higher throughput instrument lead lower price near-term
though also screen bullish overal output time final librari prep grew
y/i repres total sequenc consum revenu
instrument revenu increas y/i servic revenu increas
quarter revenu licens agreement
continu expect novaseq shipment flat slightli y/i
comment novaseq order hiseq user addit
close novaseq shipment went new-to-illumina new sequenc
custom compani still believ novaseq upgrad cycl span multipl
year roughli approxim high throughput custom
begun transit novaseq previous expect closer hiseq
custom transit novaseq end though uptak seem
slower point drive adopt broader rang custom illumina
previous announc sever chang lower-throughput flow cell strategi
novaseq compani decreas price flow cell
respect combin launch prime sp flow cell compani hope
catalyz placement lower throughput hiseq custom
model estim place novaseq placement
averag consum pull-through follow expect
placement assum novaseq
place repres replac least one hiseq compani start see
cannib hiseq custom well given rel advantag novaseq
forecast billion novaseq revenu year launch
compar million nextseq revenu million hiseq revenu
year launch assumpt model place
novaseq per year hiseq hiseq decommiss persist beyond given multi-
year adopt util increas per novaseq end
barclay research revenu build
array revenu decreas y/i quarter million softer result
driven consum servic revenu
compani anticip array revenu compar
previous guid due weaker demand environ dtc test
remind provid in-hous test servic dtc test compani notabl
segmentarray y/i miniseq instal y/i y/i stack y/i product y/i instrument instrument instrument instrument instrument miniseq instrument y/i y/i product product y/i servic y/i array y/i y/i y/i consum instrument barclay illumina inc
ancestrydna compani also supplier dtc compani run volum in-
hous partner laboratori
gener revenu consum consum
revenu grew quarter driven sequenc consum y/i
look back increas instal base instrument market consum
pull follow servic revenu revenu increas y/i
growth servic y/i partial off-set declin microarray servic
mix revenu instrument vs recur
gross margin increas y/i driven favor mix notabl ivd licens
oncolog develop revenu report sequenc servic consum
higher margin repres revenu quarter y/i compani
non-gaap gross margin y/i gross margin
expect y/i ebitda margin y/i
 ex-comp decreas y/i revenu sg ex-comp
decreas y/i revenu put togeth total oper
expens sg stock-bas comp decreas y/i revenu
non-gaap sg revenu
non-gaap ep increas y/i addit oper beat driven
ivd collabor ep growth benefit decreas compani
quarterli non-gaap ep y/i growth
growthnon-gaap epsepsy/i growth barclay illumina inc
estestestestestincom statement growth growth growth growth growth growth y/i growth product revenu ex product revenu inc product revenu inc servic servic gross gross margin inc gross margin inc growth gener growth base sg stock base opex ebitda growth oper incom ebit growth invest debt expens pre-tax pre-tax growth incom tax non-control interest net adj net growth growth net net barclay illumina inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
